M. Skalland

676 total citations · 1 hit paper
17 papers, 249 citations indexed

About

M. Skalland is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Physiology. According to data from OpenAlex, M. Skalland has authored 17 papers receiving a total of 249 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 4 papers in Epidemiology and 4 papers in Physiology. Recurrent topics in M. Skalland's work include Cystic Fibrosis Research Advances (14 papers), Pneumonia and Respiratory Infections (4 papers) and Asthma and respiratory diseases (4 papers). M. Skalland is often cited by papers focused on Cystic Fibrosis Research Advances (14 papers), Pneumonia and Respiratory Infections (4 papers) and Asthma and respiratory diseases (4 papers). M. Skalland collaborates with scholars based in United States, Canada and United Kingdom. M. Skalland's co-authors include Sonya L. Heltshe, Steven M. Rowe, Christopher H. Goss, Pradeep K. Singh, Sachinkumar B. Singh, Anh T. Vo, John P. Clancy, Peter Jorth, Jill M. Van Dalfsen and Sarah J. Morgan and has published in prestigious journals such as Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine and Journal of Pediatric Gastroenterology and Nutrition.

In The Last Decade

M. Skalland

17 papers receiving 247 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

2023 106 citations David P. Nichols, Sarah J. Morgan et al. Journal of Clinical Investigation profile →

Peers

M. Skalland

PRM

EPIDE

PHYSI

EMS

Dave P. Nichols United States

Natalia Cirilli Italy

Jill M. VanDalfsen United States

Adelina Amorim Portugal

Bernadette Prentice Australia

Andrea Browatzki Denmark

Silke van Koningsbruggen Germany

Hani Abo-Leyah United Kingdom

Sandra Scott United Kingdom

Alan Genatossio United States

Dave P. Nichols United States

M. Skalland

190 ×0.9

PRM

49 ×1.0

EPIDE

30 ×1.3

23 ×1.0

PHYSI

12 ×0.7

EMS

Citations per year, relative to M. Skalland M. Skalland (= 1×) peers Dave P. Nichols

Countries citing papers authored by M. Skalland

Since Specialization

Citations

This map shows the geographic impact of M. Skalland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Skalland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Skalland more than expected).

Fields of papers citing papers by M. Skalland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Skalland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Skalland. The network helps show where M. Skalland may publish in the future.

Co-authorship network of co-authors of M. Skalland

This figure shows the co-authorship network connecting the top 25 collaborators of M. Skalland. A scholar is included among the top collaborators of M. Skalland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Skalland. M. Skalland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Nichols, David P., Sarah J. Morgan, M. Skalland, et al.. (2023). Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. Journal of Clinical Investigation. 133(10). 106 indexed citations breakdown →

Pittman, Jessica E., M. Skalland, Scott D. Sagel, et al.. (2022). Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis. 21(6). 946–949. 6 indexed citations

VanDevanter, Donald R., Natalie E. West, Don B. Sanders, et al.. (2022). Antipseudomonal treatment decisions during CF exacerbation management. Journal of Cystic Fibrosis. 21(5). 753–758. 6 indexed citations

Psoter, Kevin J., Sonya L. Heltshe, Ruchi Jain, et al.. (2022). Evaluation of Sex Differences in Clinical Outcomes in People with Cystic Fibrosis Requiring Intravenous Antimicrobial Therapies for a Pulmonary Exacerbation: Sub-Analysis of the STOP2 Cohort. A5105–A5105. 1 indexed citations

Zemanick, Edith T., Michael W. Konstan, Donald R. VanDevanter, et al.. (2021). Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. Journal of Cystic Fibrosis. 20(6). 965–971. 16 indexed citations

Heltshe, Sonya L., et al.. (2021). C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response. Journal of Cystic Fibrosis. 21(4). 588–593. 15 indexed citations

Heltshe, Sonya L., et al.. (2021). The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis. Journal of Cystic Fibrosis. 20(6). 932–936. 6 indexed citations

West, N., Christopher H. Goss, Sonya L. Heltshe, et al.. (2021). WS09.6 A randomised clinical trial of antimicrobial duration for treatment of cystic fibrosis pulmonary exacerbations (STOP2). Journal of Cystic Fibrosis. 20. S18–S18. 2 indexed citations

Sanders, Don B., Umer Khan, Sonya L. Heltshe, et al.. (2021). Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation. Journal of Cystic Fibrosis. 21(4). 574–580. 9 indexed citations

10.

Schwarzenberg, Sarah Jane, et al.. (2021). 209: Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms: Six-month report of PROMISE GI. Journal of Cystic Fibrosis. 20. S102–S102. 1 indexed citations

11.

Sanders, Don B., Sonya L. Heltshe, M. Skalland, et al.. (2021). 153: Site of intravenous antimicrobial treatment of pulmonary exacerbations in the STOP2 study: Home versus hospital. Journal of Cystic Fibrosis. 20. S76–S77. 1 indexed citations

12.

VanDevanter, Donald R., Sonya L. Heltshe, M. Skalland, et al.. (2021). 157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response. Journal of Cystic Fibrosis. 20. S78–S78. 2 indexed citations

13.

VanDevanter, Donald R., Sonya L. Heltshe, Don B. Sanders, et al.. (2020). Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. Journal of Cystic Fibrosis. 20(1). 36–38. 11 indexed citations

14.

Nichols, Dave P., Katherine Odem‐Davis, Jonathan D. Cogen, et al.. (2019). Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 201(4). 430–437. 39 indexed citations

15.

Heltshe, Sonya L., Moira L. Aitken, Douglas B. Hornick, et al.. (2019). WS01-3 IV gallium nitrate demonstrates biological activity for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis. 18. S1–S2. 3 indexed citations

16.

Flume, Patrick A., Sonya L. Heltshe, Donald R. VanDevanter, et al.. (2018). P094 Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis. 17. S85–S85. 4 indexed citations

17.

Gelfond, Daniel, Sonya L. Heltshe, M. Skalland, et al.. (2017). Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. Journal of Pediatric Gastroenterology and Nutrition. 66(4). 657–663. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact